Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments

Description:

Introduction

After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.

Scope

- Analysis of current migraine treatment approaches and drug recommendations, patient acquisition process and unmet medical needs.


- Review of the migraine drug pipeline dynamics, including detailed profiling of key late-stage products.

- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.

Highlights

In 2019, the seven major migraine market total is forecast to reach $2.8 billion. While high generic competition will continue to dictate the US market decline, proposed or enacted price reductions in the European countries will offset the uptake of new products and inhibit growth in this region.

Sumavel DosePro (sumatriptan needleless injection; Zogenix and Astellas) and Levadex (dihydroergotamine mesylate orally inhaled; MAP Pharmaceuticals) have been designed to provide a rapid acting and convenient relief of migraine. However, high cost, associated reimbursement challenges and patient preference for oral pills will limit uptake of both.

Despite upcoming regulatory uncertainty and future reimbursement hurdles, Allergan’s Botox is set to become the first product approved for chronic migraine. Separately, while recent safety issues represent a major knock-back for Merck & Co., telcagepant is still predicted to become a useful alternative to the triptans.

Reasons to Purchase

- Quantify the current and future size of the migraine market.

- Identify potential licensing opportunities based on product portfolios and anticipated market needs.

- Understand the country-specific impact of key events in the migraine market during the forecast period 2010 to 2019.

Contents:

Overview
Catalyst
Summary
Executive Summary
Strategic scoping and focus
Datamonitor insight into the migraine market
Related reports
Upcoming related reports
1. Patient Potential
Key findings
Definition of migraine
Definition
Migraine is a chronic primary headache disorder
The five distinct stages of a migraine
Pathophysiology
Newer neurovascular theory assumes that a complex series of events initiates migraine
Etiology
Convincing genetic linkage to migraine susceptibility remains elusive
Gender ratio points to a possible genetic influence
Patient segmentation
The two major types of migraine account for the vast majority of cases
Migraine with aura affects approximately one in 10 migraineurs
Migraine without aura is the most common and also disabling subtype
Menstrual migraine affects between 50% and 60% of female migraineurs
Epidemiology
Migraine has an understated impact on population wellbeing
Seven major markets
About 10% of the general adult population are thought to suffer from migraine
Prevalence of migraine in adolescents is lower than in adults but represents an attractive indication expansion strategy
Rest of the world
Migraine prevalence appears to be similar across the globe but detailed studies are sparse
Migraine by treatment method: prophylactic and chronic migraine
Prophylactic treatment of migraine is vastly underutilized
Chronic migraine accounts for 1.4-2.2% of the general population but debate over the most accurate definition persists
Clinical unmet need in migraine
Unmet need one: sustained pain relief
Unmet need two: reduced headache relapse rates
Unmet need three: more efficacious prophylactic drugs
Unmet need four: safer and better tolerated drugs for both the acute and preventative treatment
Unmet need five: rapid onset of action
2. Market Overview
Key findings
Market definition for this report
Seven major market current and future market assessment
Future triptan genericization will see the migraine market value continue to decline through to 2019
Market volume to maintain consistent growth over forecast period
Further patent expiries and tough cost-control measures will inhibit 5EU market growth
Despite biannual price cuts Japan will represent the only growth market as demand for migraine prescriptions continues
Triptans to remain the leading class despite experiencing considerable sales decline
Rest of the world snapshot
The rest of the world migraine market accounted for 18% of the global value in 2009
Rest of the world region market value also contracted in 2009
Rest of the world accounts for half of the global migraine market volume
Non-narcotic analgesics are prescribed to a greater extent outside of the seven major markets
BRIC and MENA provide strongest historical 5-year growth
Patient acquisition process
Introduction
Patient care pathway
How to decide on acute treatment or prophylaxis
3. Brand Dynamics
Key findings
Overview of competitive landscape
The FDA approves two new acute migraine products in 2009
Reimbursement/tiering of brands
New products struggle to achieve favorable tiering in presence of generic sumatriptan and established triptan brands
Managed care actively limits the availability of the triptans
Leading brands suffer generic erosion following patent expiry

Imitrex (sumatriptan; GlaxoSmithKline)
Market-leading acute migraine brand's reign at the top comes to an end
A range of delivery method reformulations and additional indications offer patients a greater treatment choice

Topamax (topiramate; Johnson & Johnson)
Formal approval drives sales of market-leading migraine prophylactic
Once-daily medication effective at reducing the number of migraine headaches experienced

Treximet (sumatriptan + naproxen; GlaxoSmithKline/Pozen)
Drug overview
Drug profile
Product positioning
Franchise extension strategy falls short as launch date delayed
Post-marketing studies focus on probable migraine and short-acting triptan non-responders
SWOT analysis
Clinical and commercial attractiveness
Brand forecast to 2019
Tiering status and availability of generic sumatriptan to limit Treximet's market success

Sumavel DosePro (sumatriptan needleless injection; Zogenix/Astellas)
Drug overview
Drug profile
Product positioning
Rapid acting sumatriptan formulation in a simple to use, needle-free delivery system
SWOT analysis
Clinical and commercial attractiveness
Brand forecast to 2019
Niche patient population and direct competition from injectable subcutaneous sumatriptan will limit uptake

Cambia (diclofenac potassium for oral solution; Nautilus Neurosciences)
Drug overview
Drug profile
Product positioning
New diclofenac formulation provides well-tolerated fast onset of action
SWOT analysis
Clinical and commercial attractiveness
Brand forecast to 2019
Small sales force and high price point will limit returns for Cambia

4. Pipeline Overview and R&D Dynamics
Key findings
Pipeline overview
Pipeline consists of reformulations and novel mechanisms
Acute treatment remains the focus of migraine developers
A lack of Phase I and preclinical compounds suggest interest is low in migraine
A wide variety of delivery methods are present in the migraine pipeline

5. Pipeline Analysis and Forecasts: Acute Migraine Drugs
Key findings
Overview of acute migraine treatment pipeline
Comparative forecasts
Datamonitor pipeline assessment summary
Definition of current comparator therapy
Imitrex remains Datamonitor's acute migraine gold standard
Levadex (dihydroergotamine mesylate orally inhaled; MAP Pharmaceuticals)
Drug overview
Drug profile
Clinical trial data
MAP sets out final studies required for NDA submission
Phase III FREEDOM-301 trial meets all four primary efficacy endpoints
SWOT analysis
Clinical and commercial attractiveness
Satisfaction of unmet needs
Novel pharmacokinetic profile provides a rapid onset of action in a more convenient administration
New option for non-responders seeking alternative treatments
Forecasts to 2019
Levadex to become a useful alternative acute migraine medication
Telcagepant (MK-0974; Merck & Co)
Drug overview
Drug profile
Clinical trial data
Additional safety study deemed necessary to counter concerns that arose from exploratory migraine prevention study
Menstrual migraine prevention study: long-term safety evaluation through a new indication assessment
Extensive clinical program sees all Phase III studies meet primary efficacy endpoints
SWOT analysis
Clinical and commercial attractiveness
Satisfaction of unmet needs
Lack of vasoconstrictor effects and promising general tolerability profile offsets recent safety concerns
Forecasts to 2019
Telcagepant will generate significant sales as an important triptan alternative
Zelrix (sumatriptan transdermal patch; NuPathe)
Drug overview
Drug profile
Clinical trial data
Statistical significance achieved at all pre-defined 2-hour efficacy endpoints in pivotal Phase III study
Two open-label Phase III safety trials and two pharmacokinetic trials are ongoing
SWOT analysis
Clinical and commercial attractiveness
Satisfaction of unmet needs
Patch formulation provides useful new route of administration for migraine patients experiencing nausea
Forecasts to 2019
Additional sumatriptan formulation expected to struggle to gain market traction
Other drugs in development for the acute treatment of migraine
MT400-Low dose (naproxen & sumatriptan; Pozen)
Pozen exercises rights to develop low-dose Treximet formulation for ex-US territories
AZ-001 (Staccato prochlorperazine; Alexza Pharmaceuticals)
Development of orally inhaled candidate temporarily suspended as Alexza directs resources elsewhere
Phase Ib trial meets primary efficacy endpoint of 2-hour pain relief
BGG492 (Novartis)
Phase II clinical trial data awaiting for AMPA receptor antagonist
B44370 (Boehringer Ingelheim)
Boehringer Ingelheim re-enters the CGRP fold with a new oral candidate
Lasmiditan (COL-144; CoLucid Pharmaceuticals)
Selective 5HT1F agonist anticipated to deliver efficacy without vasoconstrictor activity
Dose-ranging Phase Ib study of oral lasmiditan meets primary efficacy endpoint
MTR-106 (Meditor Pharmaceuticals)
Proposed NOS inhibitor shows promise in small Phase II study
Nasal carbon dioxide (Capnia)
New Phase II study completed in 2009 for intranasal carbon dioxide candidate
NGX424 (tezampanel; Raptor Pharmaceuticals)
Injectable ionotropic glutamate receptor antagonist remains in Phase II as development partner is sought
NVD-201 (sumatriptan oral spray; Novadel Pharma)
Progress has been slow for novel oral spray sumatriptan formulation
NXN-188 (NeurAxon)
Dual-action selective nitric oxide synthase inhibitor and 5HT agonist offers promise in migraine with aura
Three active confirmative Phase II studies to evaluate NXN-188 administered as three 200mg capsules
ROX-828 (ketorolac; Roxro Pharma)
Intranasal formulation of emergency room NSAID on hold as Roxro focuses on launch of Spirix
Proof of concept Phase II study results merit further clinical investigation
Early-stage compounds in development for the acute treatment of migraine
6. Pipeline Analysis and Forecasts: Migraine Prophylaxis Drugs
Key findings
Overview of migraine prophylaxis treatment pipeline
Definition of current comparator therapy
Topamax is Datamonitor's migraine prophylaxis gold standard
Botox (onabotulinumtoxinA; Allergan)
Drug overview
Drug profile
Clinical trial data
PREEMPT clinical program forms basis of chronic migraine filing
PREEMPT 1 misses primary efficacy endpoint in reducing the frequency of headache episodes
PREEMPT 2 meets all primary and secondary headache symptom measures
SWOT analysis
Clinical and commercial attractiveness
Satisfaction of unmet needs
Seeking approval to treat the most underserved and debilitating migraine population
Difficulty predicting responders will provide a stiff clinical challenge
Forecasts to 2019
Botox will generate the majority of its sales in the US amid anticipated reimbursement challenges
Other drugs in development for the prophylactic treatment of migraine
E2007 (perampanel; Eisai)
AMPA receptor antagonist remains in Eisai’s pipeline although no development announced since 2006
Horizant (GSK1838262/XP13512/gabapentin enacarbil; XenoPort/GlaxoSmithKline)
Phase II migraine study nears completion while the FDA rejects the drug for restless legs syndrome
Tonabersat (SB-220453; Minster Pharmaceuticals)
GAP junction blocker misses primary efficacy endpoint in Phase IIb TEMPUS study
Early-stage compounds in development for the prophylactic treatment of migraine
Bibliography
Journal articles and conference abstracts
Websites
APPENDIX
Forecasting assumptions
New product launches
Patent expiries
Methodology
Datamonitor forecast methodology
Definition of a standard unit
Exchange rates
Country group definitions
Rest of European Union
Middle East and North Africa (MENA)
Rest of World
Migraine-specific sales calculations
ATC classes included in ‘others’ to define the migraine market
Datamonitor drug assessment scorecard
Acute migraine pipeline drug assessment scorecard
Migraine prophylaxis pipeline drug assessment scorecard
Contributing experts
Conference attendance
About Datamonitor
About Datamonitor Healthcare
About the Disease analysis team
Datamonitor consulting
Disclaimer
List of Tables
Table 1: One-year prevalence of migraine in the seven major markets, 2010
Table 2: Prevalence of migraine in the adult population across the seven major markets (000s), 2010
Table 3: Triptan 24 hours sustained pain-freedom rate
Table 4: Regional migraine market sales value ($m) and sales volume (IMS standard units) dynamics across the seven major markets, 2004-2018
Table 5: Global sales ($m) dynamics of the migraine market, 2005-09
Table 6: Representative formulary tier status in the US for leading acute migraine brands, 2010
Table 7: Imitrex (sumatriptan) - drug profile, 2010
Table 8: Topamax (topiramate; Johnson & Johnson) - drug profile, 2010
Table 9: Treximet (sumatriptan 85mg + naproxen sodium 500mg) - drug profile, 2010
Table 10: Datamonitor’s drug assessment scorecard for Treximet in migraine, 2010
Table 11: Sumavel DosePro (sumatriptan needleless injection; Zogenix/Astellas) - drug profile, 2010
Table 12: Datamonitor’s drug assessment scorecard for Sumavel DosePro (sumatriptan needleless injection; Zogenix/Astellas) in migraine, 2010
Table 13: Migraine-specific sales forecast for Sumavel DosePro (sumatriptan needleless injection; Zogenix/Astellas) in the seven major markets ($m), 2010-2019
Table 14: Cambia (diclofenac potassium for oral solution) - drug profile, 2010
Table 15: Pivotal Phase III clinical efficacy results of Cambia in the acute treatment of migraine
Table 16: Datamonitor's drug assessment scorecard for Cambia (diclofenac potassium for oral solution; Nautilus Neurosciences) in migraine, 2010
Table 17: Migraine-specific sales forecast for Cambia (diclofenac potassium for oral solution; Nautilus Pharmaceuticals) in the seven major markets ($m), 2010-2019
Table 18: Products in mid- to late-stage clinical development (Phase II-approved) for migraine, 2010
Table 19: Products in Phase I and preclinical development for migraine, 2010
Table 20: Products in mid-to-late stage clinical development (Phase II-pending approval) for the acute treatment of migraine, 2010
Table 21: Levadex (dihydroergotamine mesylate orally inhaled) - drug profile, 2010
Table 22: Key clinical trial data points for Levadex (dihydroergotamine mesylate orally inhaled; MAP Pharmaceuticals) from the Phase III FREEDOM-301 acute migraine study, 2009
Table 23: Datamonitor's drug assessment scorecard for Levadex (dihydroergotamine mesylate orally inhaled; MAP Pharmaceuticals) in migraine, 2010
Table 24: Migraine-specific sales forecast for Levadex (dihydroergotamine mesylate orally inhaled; MAP Pharmaceuticals) in the seven major markets ($m), 2010-2019
Table 25: Telcagepant (MK-0974) - drug profile, 2010
Table 26: Key clinical trial data points for telcagepant (MK-0974; Merck & Co) in a placebo-controlled acute migraine study announced in September 2008
Table 27: Key clinical trial data points for telcagepant (MK-0974; Merck & Co) in a placebo-controlled comparative acute migraine study announced in June 2008
Table 28: Datamonitor's drug assessment scorecard for telcagepant (MK-0974; Merck & Co.) in migraine, 2010
Table 29: Migraine-specific sales forecast for telcagepant (MK-0974; Merck & Co.) in the seven major markets ($m), 2010-19
Table 30: Impacting factors on migraine-specific revenues of telcagepant, 2010-19
Table 31: Zelrix (sumatriptan transdermal patch) - drug profile, 2010
Table 32: Key clinical trial data points for Zelrix (sumatriptan transdermal patch; NuPathe) from the Phase III acute migraine study
Table 33: Datamonitor's drug assessment scorecard for Zelrix (sumatriptan transdermal patch; NuPathe) in migraine, 2010
Table 34: Migraine-specific sales forecast for Zelrix (sumatriptan transdermal patch; NuPathe) in the seven major markets ($m), 2010-2019
Table 35: Key clinical trial data points for AZ-001 (Staccato prochlorperazine; Alexza Pharmaceuticals) from the Phase IIb acute migraine study
Table 36: Ongoing NXN-188 (NeurAxon) Phase II migraine studies, 2010
Table 37: Products in Phase I and preclinical development for the acute treatment of migraine, 2010
Table 38: Products in mid-to-late stage clinical development (Phase II-approved) for the prophylactic treatment of migraine, 2010
Table 39: Botox (onabotulinumtoxinA; Allergan) - drug profile, 2010
Table 40: Efficacy of Botox (onabotulinumtoxinA; Allergan) following the 24-week double-blind phase of the PREEMPT 1 (Phase III Research Evaluating Migraine Prophylaxis Therapy) study
Table 41: Efficacy of Botox (onabotulinumtoxinA; Allergan) following the 24-week double-blind and 56-week open-label phases of the PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therap1 study
Table 42: Datamonitor's drug assessment scorecard for Botox (onabotulinumtoxinA; Allergan) in migraine, 2010
Table 43: Migraine-specific sales forecast for Botox (onabotulinumtoxinA; Allergan) in the seven major markets ($m), 2010-19
Table 44: Impacting factors on migraine-specific revenues of Botox (onabotulinumtoxinA; Allergan), 2010-19
Table 45: Products in Phase I and preclinical development for the prophylactic treatment of migraine, 2010
Table 46: Datamonitor's launch date estimation for migraine products in the US, SEU and Japan, 2010-2019
Table 47: Patent expiry dates for key migraine brands in the seven major markets, 2010-2019
Table 48: Other ATC classes included for migraine market definition, 2008
Table 49: Datamonitor's drug assessment parameters for key late-stage acute migraine pipeline therapies
Table 50: Datamonitor's drug assessment parameters for key late-stage migraine prophylaxis pipeline therapies

List of Figures
Figure 41: Methodology for forecasting price to remove impact of currency fluctuations on future trend

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/1289443/">http://www.researchandmarkets.com/reports/1289443/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCHZLD37</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 38000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 15200</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World